Alluvi BPC-157 & TB-500 40mg Recovery Peptide Pen
Product Description
Alluvi BPC-157 & TB-500 40mg Recovery Peptide Pen is a premium research-grade injectable designed to accelerate healing, reduce inflammation, and support tissue regeneration. This pre-filled pen combines two of the most powerful peptides in regenerative science: BPC-157, known for its angiogenic and anti-inflammatory properties, and TB-500, recognized for enhancing cellular migration and collagen synthesis.
Researchers and clinicians rely on this synergistic blend to study recovery outcomes in muscle injuries, tendon ruptures, ligament tears, and post-surgical healing. The 40mg formulation delivers consistent dosing and convenience, eliminating the need for manual mixing or reconstitution. Buy Original Alluvi Pens in the UK
Each pen comes from sterile lab conditions, meeting strict purity standards. The solution stays in a stable carrier to ensure long shelf life and precise injections. Made for non-human research, this product suits labs, universities, and biotech professionals conducting advanced regenerative medicine studies.
Key Benefits:
- Supports rapid tissue repair and recovery
- Reduces inflammation and scar tissue formation
- Enhances flexibility and joint mobility
- Promotes angiogenesis and cellular regeneration
- Convenient pre-filled format for consistent dosing
Usage Guidelines: Use this product only for research purposes. Do not use it for human or veterinary applications. Keep it in a cool, dry place and follow all lab safety protocols when handling.
Shipping & Packaging: We ship orders discreetly with cold packs to maintain peptide integrity. Enjoy fast global delivery and secure checkout options.
Why Choose Buy Alluvi Pens? We specialize in high-purity peptide injectors for research professionals. Our Alluvi pens are trusted for their consistency, quality, and scientific reliability. With responsive support and transparent sourcing, we help you focus on what matters — your research.
Buy 1000 mg Edible
Reviews
There are no reviews yet.